Eli Lilly's (LLY) oral GLP-1 drug, orforglipron, met expectations in the phase 3 Achieve-1 trial for type 2 diabetes and reduced hemoglobin A1C with a weight loss of 16 pounds at the highest dose, Truist Securities said in a note on Thursday.
The firm said that the company plans to file for approval of the drug for obesity by year-end and for type two diabetes in 2026, with results of two major obesity focused trials expected in Q3.
Truist said that it does not expect Lilly to face the same supply constraints as current GLP-1 injectables when manufacturing orforglipron and global investments support the potential for a broad commercial launch.
The firm models peak global sales of orforglipron at about $14.7 billion, compared with a consensus estimate of $16.8 billion.
Truist reiterated its buy rating on Lilly's stock and kept the price target unchanged at $1,038.
Price: 828.95, Change: +94.05, Percent Change: +12.80
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.